As per the Jan 28 announcement, regarding DKD, I think the treatment (legacy effect) order, with a longer design duration with more patients is important to note. The question is, does Dimerix do phase 2 or go to phase 3? Interestingly, that announcement coincided with the 4 year anniversary of a patient receiving dmx-200. In a small group of patients, they have like a phase 4 surveillance, longitudinal study already happening. They must be getting some feedback from the doctor but with privacy considerations, is it enough to understand the treatment order enough? Fortunately we have expert doctors to guide us. Hoping for some positive news soon on many options. GLTH
Ann: Half Year Report and Update, page-67
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
36.0¢ |
Change
0.025(7.46%) |
Mkt cap ! $197.8M | |||
| Open | High | Low | Value | Volume |
| 34.0¢ | 36.3¢ | 33.5¢ | $3.801M | 10.73M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 20000 | 36.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 36.5¢ | 378856 | 6 |
View Market Depth
| Last trade - 16.10pm 03/05/2024 (20 minute delay) ? |
|
|||||
|
Last
36.0¢ |
Change
0.025 ( 7.33 %) |
||||
| Open | High | Low | Volume | ||
| 33.5¢ | 36.5¢ | 33.5¢ | 5557634 | ||
| Last updated 15.58pm 03/05/2024 ? | |||||
| DXB (ASX) Chart |